Imfinzi (durvalumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Imfinzi (durvalumab) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth in the historic period can be attributed to expanded indications and approvals, the increasing demand for targeted therapies, growing patient interest in personalized treatments, advancements in immunotherapy, and rising patient demand for immunotherapies.

Market growth during the forecast period is driven by the growing use of combination therapies, increased pharmaceutical R&D, rising cancer prevalence, greater acceptance of immunotherapy, expanding regulatory influence, and increased investment in healthcare infrastructure. Key trends in the forecast period include the adoption of personalized medicine, a focus on biosimilars, integration of AI and machine learning, and collaborations between pharmaceutical companies.

The growing incidence of cancer is expected to drive the growth of the imfinzi (durvalumab) market. Cancer, a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, is becoming increasingly prevalent due to an aging population, smoking, poor diet, and obesity, all of which contribute to higher cancer rates. Durvalumab (Imfinzi) is used to treat cancer by inhibiting the PD-L1 protein, which prevents cancer cells from evading detection by the immune system. According to the National Cancer Institute (NIH), there were 18.1 million cancer survivors in the U.S. in 2022, with that number expected to rise to 22.5 million by 2032. The rising incidence of cancer is thus driving the demand for imfinzi in the market.

Rising personalized medicine is expected to propel the growth of the imfinzi (durvalumab) market. Personalized medicine tailors treatments based on individual patient characteristics such as genetic makeup, lifestyle, and environment to achieve the most effective outcomes. The demand for personalized treatments is growing due to advancements in genomic technologies, molecular biology, precision diagnostic tools, and targeted therapies that improve patient outcomes while minimizing side effects. Imfinzi, by targeting the PD-L1 protein, plays a critical role in personalized medicine by enabling tailored immunotherapy treatments for cancer patients, improving efficacy and reducing side effects. According to the Personalized Medicine Coalition, the FDA approved personalized medicines for 34% of new drugs in 2022, emphasizing the increasing focus on individualized therapies. Therefore, the rise in personalized medicine is a significant driver for the imfinzi market.

A key trend in the imfinzi (durvalumab) market is the focus on gaining regulatory approvals to expand its use for additional cancer types, enhance clinical indications, and broaden its market reach. Regulatory approvals from authorities like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) allow for the marketing and use of drugs in specific regions. For example, in September 2022, AstraZeneca received FDA approval for durvalumab (Imfinzi) to treat locally advanced or metastatic biliary tract cancer (BTC) in adults. This approval was based on the results of the TOPAZ-1 trial, which showed that durvalumab combined with gemcitabine and cisplatin significantly improved overall survival and progression-free survival in patients with BTC. The success of such trials and regulatory approvals is expected to increase the market reach of Imfinzi, further driving its growth.

Key player operating in the imfinzi (durvalumab) market is AstraZeneca PLC.

North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in imfinzi (durvalumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the imfinzi (durvalumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Imfinzi (durvalumab) is a human monoclonal antibody and immunotherapy drug designed to block programmed death-ligand 1 (PD-L1), a protein that tumors use to evade immune system detection. It is used to treat various cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, and advanced urothelial carcinoma.

The primary types of imfinzi (durvalumab) include 2.4 mL injection and 10 mL injection. The 2.4 mL injection refers to a precise volume of the drug contained in a 2.4 milliliter vial or syringe, often used for accurate dosing during medical treatments. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies for applications such as locally advanced urothelial carcinoma, metastatic urothelial carcinoma, and other indications.

The imfinzi (durvalumab) market research report is one of a series of new reports that provides imfinzi (durvalumab) market statistics, including imfinzi (durvalumab) industry global market size, regional shares, competitors with imfinzi (durvalumab) market share, detailed imfinzi (durvalumab) market segments, market trends and opportunities, and any further data you may need to thrive in the imfinzi (durvalumab) industry. This Imfinzi (durvalumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The imfinzi (durvalumab) market consists of sales of products including Keytruda, Opdivo, Tecentriq, Libtayo, Bavencio and Emerging PD-1/PD-L1 Inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.